The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Lowering Uric Acid with Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia
Abstract
Background: Hyperuricemia is an independent predictor of impaired fasting glucose and type 2 diabetes, but whether it has a causal role in insulin resistance remains controversial. Here we tested the hypothesis that lowering uric acid in hyperuricemic nondiabetic subjects might improve insulin resistance. Methods: Subjects with asymptomatic hyperuricemia (n = 73) were prospectively placed on allopurinol (n = 40) or control (n = 33) for 3 months. An additional control group consisted of 48 normouricemic subjects. Serum uric acid, fasting glucose, fasting insulin, HOMA-IR (homeostatic model assessment of insulin resistance), and high-sensitivity C-reactive protein were measured at baseline and at 3 months. Results: Allopurinol-treated subjects showed a reduction in serum uric acid in association with improvement in fasting blood glucose, fasting insulin, and HOMA-IR index, as well as a reduction in serum high-sensitivity C-reactive protein. The number of subjects with impaired fasting glucose significantly decreased in the allopurinol group at 3 months compared with baseline (n = 8 [20%] vs n = 30 [75%], 3 months vs baseline, P < 0.001). In the hyperuricemic control group, only glucose decreased significantly and, in the normouricemic control, no end point changed. Conclusions: Allopurinol lowers uric acid and improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. Larger clinical trials are recommended to determine if lowering uric acid can help prevent type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Cited by
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Self-citationHyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 435
Self-citationUric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2016.11.004 · Cited by 417
Physiology of Hyperuricemia and Urate-Lowering Treatments
Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00160 · Cited by 319
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
Copur, S., Demiray, A., & Kanbay, M. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.022 · Cited by 287
Self-citation
Metadata
- Authors
- Takir, M., Kostek, O., Ozkok, A., Elcioglu, O. C., Bakan, A., Erek, A., Mutlu, H. H., Telci, O., Semerci, A., Odabas, A. R., Afsar, B., Smits, G., Alanaspa, M., Sharma, S., Johnson, R. J., & Kanbay, M.
- Venue
- Journal of Investigative Medicine
- Publisher
- SAGE Publications
- Published
- 2015-12
- Volume
- 63
- Issue
- 8
- Pages
- 924-929
- ISSN
- 1081-5589 (ISSN-L)
- 1708-8267
- OpenAlex
- W2272417494
- Cited by
- 174
- References
- 1
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lowering Uric Acid with Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. https://app.cochat.ai/papers/10.1097/jim.0000000000000242
- The paper
- Takir, M., Kostek, O., Ozkok, A., Elcioglu, O. C., Bakan, A., Erek, A., Mutlu, H. H., Telci, O., Semerci, A., Odabas, A. R., Afsar, B., Smits, G., Alanaspa, M., Sharma, S., Johnson, R. J., & Kanbay, M. (2015). Lowering Uric Acid with Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. Journal of Investigative Medicine. https://doi.org/10.1097/jim.0000000000000242
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.